文献速递临床试验与 GCP

金雀花碱与伐尼克兰对戒烟效果比较:一项随机临床试验

Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该非劣效性开放标签随机临床试验在澳大利亚纳入1452名每日吸烟的成人,比较25天金雀花碱与84天伐尼克兰方案的戒烟效果。7个月时一氧化碳验证的6个月持续戒断率分别为11.7%和13.3%,风险差-1.62%(单侧97.5%CI -5.02%至∞),未达到预设的5%非劣效界值;金雀花碱组自我报告的不良事件发生率较低。

要点

  • 金雀花碱25天方案在6个月持续戒断率上未能证明不劣于伐尼克兰84天方案
  • 金雀花碱组不良事件报告率低于伐尼克兰组(IRR 0.88,95%CI 0.81-0.95)
  • 两组戒断率绝对值接近(11.7% vs 13.3%),但非劣效性统计检验未通过

核心结论

  • 在愿意戒烟的每日吸烟者中,25天金雀花碱治疗与84天伐尼克兰治疗相比,在戒烟方面未能证明非劣效性。

研究设计与样本

  • 非劣效性、开放标签随机临床试验,采用分配隐藏和盲法结局评估,于2017年11月至2019年5月在澳大利亚开展,随访至2020年1月完成。
  • 共纳入1452名愿意尝试戒烟的澳大利亚成年每日吸烟者,随机分为金雀花碱组(n=725)和伐尼克兰组(n=727)。
  • 金雀花碱按厂家推荐剂量给药:1.5 mg胶囊,初始每日6次,25天疗程内逐渐减量。
  • 伐尼克兰按厂家推荐剂量给药:0.5 mg片剂滴定至1 mg每日两次,共84天(12周)。
  • 所有参与者均获得转介至标准电话行为支持的機會;数据收集主要通过计算机辅助电话访谈,但主要结局需面对面访视验证。

主要发现

  • 7个月随访时一氧化碳呼气试验验证的6个月持续戒断率:金雀花碱组11.7%,伐尼克兰组13.3%。
  • 金雀花碱组自我报告不良事件发生频率较低(482名参与者中共997起事件),伐尼克兰组为510名参与者中共1206起事件。

关键数值与推荐

  • 主要结局为7个月随访时经一氧化碳呼气试验验证的6个月持续戒断。
  • 共1452名参与者随机分组,平均(标准差)年龄42.9(12.7)岁,742名(51.1%)为女性,1108名(76.3%)完成试验。

临床怎么用

  • 对于愿意戒烟的每日吸烟者,25天金雀花碱方案在戒烟效果上未能证明不劣于84天伐尼克兰方案,临床选择需综合疗效与不良事件耐受性。
  • 金雀花碱组不良事件报告率较低,或可作为无法耐受伐尼克兰者的替代考虑,但需告知其非劣效性未被证实。

局限性

  • 开放标签设计可能影响参与者报告的不良事件和依从性。
  • 完成试验比例为76.3%,失访可能对结果产生偏倚。
  • 非劣效性检验未通过,不能排除金雀花碱劣于伐尼克兰的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cytisine is more effective than placebo and nicotine replacement therapy for smoking cessation. However, cytisine has not been tested against the most effective smoking cessation medication, varenicline, which is associated with adverse events known to lead to discontinuation of therapy. OBJECTIVE: To examine whether standard cytisine treatment (25 days) was at least as effective as standard varenicline treatment (84 days) for smoking cessation. DESIGN, SETTING, AND PARTICIPANTS: This noninferiority, open-label randomized clinical trial with allocation concealment and blinded outcome assessment was undertaken in Australia from November 2017 through May 2019; follow-up was completed in January 2020. A total of 1452 Australian adult daily smokers willing to make a quit attempt were included. Data collection was conducted primarily by computer-assisted telephone interview, but there was an in-person visit to validate the primary outcome. INTERVENTIONS: Treatments were provided in accordance with the manufacturers' recommended dosage: cytisine (n = 725), 1.5-mg capsules taken 6 times daily initially then gradually reduced over the 25-day course; varenicline (n = 727), 0.5-mg tablets titrated to 1 mg twice daily for 84 days (12 weeks). All participants were offered referral to standard telephone behavioral support. MAIN OUTCOMES AND MEASURES: The primary outcome was 6-month continuous abstinence verified using a carbon monoxide breath test at 7-month follow-up. The noninferiority margin was set at 5% and the 1-sided significance threshold was set at .025. RESULTS: Among 1452 participants who were randomized (mean [SD] age, 42.9 [12.7] years; 742 [51.1%] women), 1108 (76.3%) completed the trial. Verified 6-month continuous abstinence rates were 11.7% for the cytisine group and 13.3% for the varenicline group (risk difference, -1.62% [1-sided 97.5% CI, -5.02% to ∞]; P = .03 for noninferiority). Self-reported adverse events occurred less frequently in the cytisine group (997 events among 482 participants) compared with the varenicline group (1206 events among 510 participants) and the incident rate ratio was 0.88 (95% CI, 0.81 to 0.95; P = .002). CONCLUSIONS AND RELEVANCE: Among daily smokers willing to quit, cytisine treatment for 25 days, compared with varenicline treatment for 84 days, failed to demonstrate noninferiority regarding smoking cessation. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12616001654448.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Courtney RJ, McRobbie H, Tutka P, et al. Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2021. PMID: 34228066. doi:10.1001/jama.2021.7621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。